Ligand Binding Assay Critical Reagents and Their Stability: Recommendations and Best Practices from the Global Bioanalysis Consortium Harmonization Team

The L4 Global Harmonization Team on reagents and their stability focused on the management of critical reagents for pharmacokinetic, immunogenicity, and biomarker ligand binding assays. Regulatory guidance recognizes that reagents are important for ligand binding assays but do not address numerous aspects of critical reagent life cycle management. Reagents can be obtained from external vendors or developed internally, but regardless of their source, there are numerous considerations for their reliable long-term use. The authors have identified current best practices and provided recommendations for critical reagent lot changes, stability management, and documentation.

[1]  T. Laird Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals , 2013 .

[2]  Philip Timmerman,et al.  The European Bioanalysis Forum community's evaluation, interpretation and implementation of the European Medicines Agency guideline on Bioanalytical Method Validation. , 2013, Bioanalysis.

[3]  Tong-Yuan Yang,et al.  Characterization of critical reagents in ligand-binding assays: enabling robust bioanalytical methods and lifecycle management. , 2013, Bioanalysis.

[4]  T. Randolph,et al.  Physical Instability of Peptides and Proteins , 2012 .

[5]  Edward Tabler,et al.  Validation and life-cycle management of a quantitative ligand-binding assay for the measurement of Nulojix(®), a CTLA-4-Fc fusion protein, in renal and liver transplant patients. , 2012, Bioanalysis.

[6]  Denise M O'Hara,et al.  Ligand Binding Assays in the 21st Century Laboratory: Recommendations for Characterization and Supply of Critical Reagents , 2012, The AAPS Journal.

[7]  T. Munro,et al.  Stabilization of a monoclonal antibody during purification and formulation by addition of basic amino acid excipients , 2011 .

[8]  Apollon Papadimitriou,et al.  Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents. , 2011, Bioanalysis.

[9]  B. Yeung,et al.  Physical Stability of Protein Pharmaceuticals , 2010 .

[10]  Feroz Jameel,et al.  Formulation and process development strategies for manufacturing biopharmaceuticals , 2010 .

[11]  K. Chattopadhyay,et al.  Role of Protein Stabilizers on the Conformation of the Unfolded State of Cytochrome c and Its Early Folding Kinetics , 2010, The Journal of Biological Chemistry.

[12]  Masood N. Khan,et al.  Development of Ligand‐Binding Assays for Drug Development Support , 2009 .

[13]  P. Krause Goals of stability evaluation throughout the vaccine life cycle. , 2009, Biologicals : journal of the International Association of Biological Standardization.

[14]  Anika Ashok,et al.  ICH Harmonised Tripartite Guideline , 2009 .

[15]  J. Darden,et al.  Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories. , 2008, Journal of pharmaceutical and biomedical analysis.

[16]  Alex Ni,et al.  Antimicrobial preservative use in parenteral products: past and present. , 2007, Journal of pharmaceutical sciences.

[17]  Denise M O'Hara,et al.  Critical ligand binding reagent preparation/selection: When specificity depends on reagents , 2007, The AAPS Journal.

[18]  Eric Woolf,et al.  Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples , 2007, The AAPS Journal.

[19]  Vinod P. Shah,et al.  Workshop/conference report—Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays , 2007, The AAPS Journal.

[20]  David M Bunk,et al.  Characterization of a new certified reference material for human cardiac troponin I. , 2006, Clinical chemistry.

[21]  Stanley B. Davis,et al.  Quality Management , 2005 .

[22]  George Scott,et al.  Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. , 2004, Journal of immunological methods.

[23]  Binodh DeSilva,et al.  Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules , 2003, Pharmaceutical Research.

[24]  G. Anderson,et al.  Determination of product shelf life and activation energy for five drugs of abuse. , 1991, Clinical chemistry.

[25]  T. Kirkwood,et al.  Predicting the stability of biological standards and products. , 1977, Biometrics.

[26]  W Greg Miller,et al.  Commutability limitations influence quality control results with different reagent lots. , 2011, Clinical chemistry.

[27]  John W. A. Findlay,et al.  Ligand-binding assays : development, validation, and implementation in the drug development arena , 2010 .

[28]  S. Frokjaer,et al.  Pharmaceutical Formulation Development Of Peptides And Proteins , 2009 .

[29]  Wei Wang,et al.  Antibody structure, instability, and formulation. , 2007, Journal of pharmaceutical sciences.

[30]  H. Selbmann [What is "quality management"?]. , 1995, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[31]  C. Burtis Tietz textbook of Clinical Chemistry , 1994 .